MX9306841A - Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos. - Google Patents

Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos.

Info

Publication number
MX9306841A
MX9306841A MX9306841A MX9306841A MX9306841A MX 9306841 A MX9306841 A MX 9306841A MX 9306841 A MX9306841 A MX 9306841A MX 9306841 A MX9306841 A MX 9306841A MX 9306841 A MX9306841 A MX 9306841A
Authority
MX
Mexico
Prior art keywords
mammals
vaccine against
based vaccine
helicobacter infection
against helicobacter
Prior art date
Application number
MX9306841A
Other languages
English (en)
Inventor
Pierre Michetti
Andre Blum
Catherine Davin
Rainer Haas
Irene Corthesy-Theulaz
Jean-Pierre Kraehenbuhl
Emilia Saraga
Original Assignee
Fundation Pour La Rech Des Mal
Gastro Intestinales Gastrofond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25517797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9306841(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundation Pour La Rech Des Mal, Gastro Intestinales Gastrofond filed Critical Fundation Pour La Rech Des Mal
Publication of MX9306841A publication Critical patent/MX9306841A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Se describe un método para provocar en un huésped mamífero una respuestainmunoprotectora a la infección por Helicobacter, mediante laadministración al huésped de una cantidad inmunológicamente efectiva deuna ureasa de Helicobacter o subunidades de ureasa como antígeno. Seproporcionan también las composiciones de vacuna.
MX9306841A 1992-11-03 1993-11-03 Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos. MX9306841A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97099692A 1992-11-03 1992-11-03
US08/085,938 US5972336A (en) 1992-11-03 1993-07-06 Urease-based vaccine against helicobacter infection

Publications (1)

Publication Number Publication Date
MX9306841A true MX9306841A (es) 1995-01-31

Family

ID=25517797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306841A MX9306841A (es) 1992-11-03 1993-11-03 Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos.

Country Status (29)

Country Link
US (1) US5972336A (es)
EP (2) EP1170016A3 (es)
JP (1) JPH07503255A (es)
KR (1) KR100287424B1 (es)
CN (1) CN1111429C (es)
AT (1) ATE217196T1 (es)
AU (2) AU678195C (es)
BR (1) BR9305711A (es)
CA (1) CA2127283A1 (es)
CZ (1) CZ284416B6 (es)
DE (1) DE69331901T2 (es)
DK (1) DK0625053T3 (es)
ES (1) ES2176232T3 (es)
FI (1) FI112032B (es)
GE (1) GEP20012429B (es)
HU (1) HU219760B (es)
IL (1) IL107474A (es)
MX (1) MX9306841A (es)
NO (1) NO942490L (es)
NZ (2) NZ299149A (es)
OA (1) OA10087A (es)
PL (1) PL174448B1 (es)
PT (1) PT625053E (es)
RO (1) RO114870B1 (es)
RU (1) RU2125891C1 (es)
SG (1) SG70978A1 (es)
SK (1) SK280619B6 (es)
WO (1) WO1994009823A1 (es)
ZA (1) ZA938203B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
JPH08509873A (ja) 1993-05-19 1996-10-22 アンスティテュ・パストゥール ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
WO1995003824A1 (en) * 1993-07-27 1995-02-09 Csl Limited Treatment of h. pylori associated gastroduodenal disease
AUPM612494A0 (en) * 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
AU702878B2 (en) * 1994-06-08 1999-03-11 Csl Limited Treatment and prevention of helicobacter infection
EP0769018B1 (en) * 1994-07-01 2002-12-18 Chiron Corporation Helicobacter proteins and vaccines
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine
PL185013B1 (pl) * 1995-04-28 2003-01-31 Oravax Inc Szczepionka do indukowania odpowiedzi immunologicznej i zestaw farmaceutyczny
WO1997005267A2 (en) * 1995-07-26 1997-02-13 Maxim Pharmaceuticals Mucosal delivery of polynucleotides
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
AU7537598A (en) * 1997-04-30 1998-11-24 Pasteur Merieux Serums Et Vaccins Dna based anti-(helicobacter) vaccine composition
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US5985631A (en) 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
CA2335487A1 (en) 1998-06-19 1999-12-23 Merieux Oravax Lt and ct in parenteral immunization methods against helicobacter infection
US6190667B1 (en) * 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
AU8464398A (en) * 1998-07-16 2000-02-07 Cheil Jedang Corporation Urease based vaccine against (helicobacter) infection
CA2361377C (en) * 1999-02-05 2009-02-03 Alk-Abello A/S Novel mucosal delivery system
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
DK2116257T3 (da) 2000-08-09 2013-02-04 Alk Abello As Parenterale vaccineformuleringer og anvendelser deraf
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
AUPR524101A0 (en) * 2001-05-25 2001-06-21 Council Of The Queensland Institute Of Medical Research, The Antigen targeting
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
CA2449663A1 (en) * 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN100460014C (zh) * 2006-07-20 2009-02-11 中国人民解放军第三军医大学 基于尿素酶b亚单位活性片段的幽门螺杆菌疫苗及其制备方法
CA2668984A1 (en) * 2006-11-10 2008-05-15 Barry J. Marshall Methods and devices for the delivery of peptides into the gastric mucosa
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR100982489B1 (ko) * 2007-12-17 2010-09-15 대구한의대학교산학협력단 헬리코박터 파일로리로부터 유래된 항원을 이용하여헬리코박터 파일로리 특이 항체 생산을 위한 백신을제조하는 방법
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) * 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
PL218700B1 (pl) 2012-03-29 2015-01-30 Gdański Univ Medyczny Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP2837939A1 (en) * 2013-08-13 2015-02-18 Technische Universität München Method for the detection of H.pylori infection
RU2696876C2 (ru) 2013-11-04 2019-08-07 Ютиай Лимитед Партнершип Способы и композиции для устойчивой иммунотерапии
EP3291832A4 (en) 2015-05-06 2018-09-12 UTI Limited Partnership Nanoparticle compositions for sustained therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JPH04169539A (ja) * 1990-11-01 1992-06-17 Imuno Japan:Kk 消化器疾患治療・予防剤およびその製造方法
CA2109088A1 (en) * 1991-04-26 1992-10-27 Emanuel Calenoff Methods to detect and treat diseases caused by bacterial allergens
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US5859219A (en) * 1992-02-26 1999-01-12 Vanderbilt University Purified vacuolating toxin from Helicobacter pylori and methods to use same
WO1993018150A1 (en) * 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US6258359B1 (en) * 1993-05-19 2001-07-10 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US5681736A (en) * 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine

Also Published As

Publication number Publication date
EP0625053B1 (en) 2002-05-08
BR9305711A (pt) 1997-02-18
IL107474A (en) 1998-09-24
OA10087A (en) 1996-12-18
ES2176232T3 (es) 2002-12-01
HU9402261D0 (en) 1994-10-28
US5972336A (en) 1999-10-26
DK0625053T3 (da) 2002-08-12
HU219760B (hu) 2001-07-30
SG70978A1 (en) 2000-03-21
SK79394A3 (en) 1996-09-04
NO942490L (no) 1994-08-22
SK280619B6 (sk) 2000-05-16
CZ160994A3 (en) 1995-04-12
IL107474A0 (en) 1994-02-27
NO942490D0 (no) 1994-07-01
CN1094640A (zh) 1994-11-09
ZA938203B (en) 1994-06-09
KR100287424B1 (ko) 2001-04-16
AU678195B2 (en) 1997-05-22
AU2003270987A1 (en) 2004-01-22
WO1994009823A1 (en) 1994-05-11
PT625053E (pt) 2002-09-30
AU5561994A (en) 1994-05-24
FI943171A0 (fi) 1994-07-01
FI112032B (fi) 2003-10-31
EP1170016A2 (en) 2002-01-09
CA2127283A1 (en) 1994-05-11
PL304419A1 (en) 1995-01-09
HUT69938A (en) 1995-09-28
EP0625053A1 (en) 1994-11-23
RU2125891C1 (ru) 1999-02-10
JPH07503255A (ja) 1995-04-06
FI943171A (fi) 1994-09-01
PL174448B1 (pl) 1998-07-31
RO114870B1 (ro) 1999-08-30
EP1170016A3 (en) 2002-03-06
GEP20012429B (en) 2001-05-25
AU678195C (en) 2003-06-12
NZ299149A (en) 1997-12-19
DE69331901D1 (de) 2002-06-13
CN1111429C (zh) 2003-06-18
CZ284416B6 (cs) 1998-11-11
NZ258118A (en) 1997-04-24
ATE217196T1 (de) 2002-05-15
DE69331901T2 (de) 2002-10-31

Similar Documents

Publication Publication Date Title
MX9306841A (es) Vacuna a base de ureasa contra la infeccion por helicobacter en mamiferos.
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
ATE139258T1 (de) Erzeugung xenogener antikörper
ES2179105T3 (es) Adyuvantes proteinicos.
NO165478C (no) Fremgangsmaate for fremstilling av antigeniske preparater.
SE8005824L (sv) Vaccin av hudparvovirus samt forfarande for dess framstellning
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
ATE244578T1 (de) Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
CY1112149T1 (el) Μειωση της παρεμβολης μεταξυ επικουρων που περιεχουν ελαιο και αντιγονων που περιεχουν τασιενεργο
ES2106032T3 (es) Vacuna para inmunizar gatos contra el desprendimiento de oocistos de toxoplasma.
FI875015A0 (fi) Vaccin mot juverinflammation.
BR0014666A (pt) Vacina
MX9306016A (es) Metodo para incrementar respuestas inmunes mediadas por celulas.
NO175846C (no) Fremgangsmåte for å oppnå et immunogen
ATE329615T1 (de) Borrelia burgdorferi bacterin
DK0485463T3 (da) Svækket hundeparvovirus (CPV), vaccine omfattende CPV og fremgangsmåde til forebyggelse af CPV-infektion i hunde
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
ATE318300T1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
ES2059605T3 (es) Vacuna toxoide de la tosferina.
ATE439857T1 (de) Lipoglykan zusammensetzungen und methoden zur behandlung von parasitischen infektionen

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees